BACKGROUND AND PURPOSE: Subcortical ischemic vascular disease (SIVD) is a major form of vascular cognitive impairment (VCI) due to small vessel disease. Matrix metalloproteinases (MMPs) are neutral proteases that disrupt the blood-brain barrier and degrade myelin basic protein under conditions of neuroinflammation. Brain tissues and cerebrospinal fluid (CSF) of patients with VCI have increased levels of MMPs. We hypothesized that patients with SIVD have increased MMPs in the CSF, which are associated with increased CSF albumin. METHODS: We studied 60 patients with suspected VCI. Twenty-five were classified as SIVD, whereas other groups included mixed Alzheimer disease and VCI, multiple strokes, and leukoaraiosis when white matter lesions were present and the diagnosis of VCI was uncertain. MMP-2 and MMP-9 in CSF and plasma were measured by gel zymography and indexed to CSF and plasma albumin. MMP-3 activity was measured by fluorescent assay. RESULTS: We found reduced MMP-2 index (P<0.001) in the CSF for the full group of patients (SIVD, multiple strokes, mixed Alzheimer disease and VCI, and leukoaraiosis) compared with control subjects, whose CSF was obtained during spinal anesthesia. MMP-3 activity was increased in VCI compared with control subjects (P<0.01). In SIVD, MMP-2 index showed a negative correlation with albumin index, which was absent with the MMP-9 index. Combining MMP-2 index and MMP-3 activity separated the patients with SIVD from the control subjects with high specificity (P<0.0005). CONCLUSIONS: Our results support the hypothesis that MMPs are associated with increased CSF albumin and suggest that they may contribute to the pathophysiology of SIVD.
BACKGROUND AND PURPOSE:Subcortical ischemic vascular disease (SIVD) is a major form of vascular cognitive impairment (VCI) due to small vessel disease. Matrix metalloproteinases (MMPs) are neutral proteases that disrupt the blood-brain barrier and degrade myelin basic protein under conditions of neuroinflammation. Brain tissues and cerebrospinal fluid (CSF) of patients with VCI have increased levels of MMPs. We hypothesized that patients with SIVD have increased MMPs in the CSF, which are associated with increased CSF albumin. METHODS: We studied 60 patients with suspected VCI. Twenty-five were classified as SIVD, whereas other groups included mixed Alzheimer disease and VCI, multiple strokes, and leukoaraiosis when white matter lesions were present and the diagnosis of VCI was uncertain. MMP-2 and MMP-9 in CSF and plasma were measured by gel zymography and indexed to CSF and plasma albumin. MMP-3 activity was measured by fluorescent assay. RESULTS: We found reduced MMP-2 index (P<0.001) in the CSF for the full group of patients (SIVD, multiple strokes, mixed Alzheimer disease and VCI, and leukoaraiosis) compared with control subjects, whose CSF was obtained during spinal anesthesia. MMP-3 activity was increased in VCI compared with control subjects (P<0.01). In SIVD, MMP-2 index showed a negative correlation with albumin index, which was absent with the MMP-9 index. Combining MMP-2 index and MMP-3 activity separated the patients with SIVD from the control subjects with high specificity (P<0.0005). CONCLUSIONS: Our results support the hypothesis that MMPs are associated with increased CSF albumin and suggest that they may contribute to the pathophysiology of SIVD.
Authors: R Schmidt; Ph Scheltens; T Erkinjuntti; L Pantoni; H S Markus; A Wallin; F Barkhof; F Fazekas Journal: Neurology Date: 2004-07-13 Impact factor: 9.910
Authors: John C Adair; Julius Charlie; John E Dencoff; Jeffrey A Kaye; Joseph F Quinn; Richard M Camicioli; William G Stetler-Stevenson; Gary A Rosenberg Journal: Stroke Date: 2004-04-22 Impact factor: 7.914
Authors: Robert D Bell; Ethan A Winkler; Itender Singh; Abhay P Sagare; Rashid Deane; Zhenhua Wu; David M Holtzman; Christer Betsholtz; Annika Armulik; Jan Sallstrom; Bradford C Berk; Berislav V Zlokovic Journal: Nature Date: 2012-05-16 Impact factor: 49.962
Authors: Yi Yang; Eduardo Candelario-Jalil; Jeffrey F Thompson; Eloy Cuadrado; Eduardo Y Estrada; Anna Rosell; Joan Montaner; Gary A Rosenberg Journal: J Neurochem Date: 2009-10-15 Impact factor: 5.372
Authors: Ping Yan; Alec Zhu; Fan Liao; Qingli Xiao; Andrew Kraft; Ernie Gonzales; Ron Perez; Steven M Greenberg; David Holtzman; Jin-Moo Lee Journal: Stroke Date: 2015-05-05 Impact factor: 7.914
Authors: Zachary A Corbin; Natalia S Rost; Svetlana Lorenzano; Walter N Kernan; Michael K Parides; Jeffrey B Blumberg; Paul E Milbury; Ken Arai; Sophia N Hartdegen; Eng H Lo; Steven K Feske; Karen L Furie Journal: J Stroke Cerebrovasc Dis Date: 2014-01-16 Impact factor: 2.136
Authors: James C Root; Kane O Pryor; Robert Downey; Yesne Alici; Marcus L Davis; Andrei Holodny; Beatriz Korc-Grodzicki; Tim Ahles Journal: Psychooncology Date: 2013-03-04 Impact factor: 3.894